Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ADMA Biologics Inc
ADMA | US
15.81
USD0.42
2.73%
ADMA | US
About ADMA Biologics Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
09/03/2026
Close
15.81
Open
15.68
High
15.92
Low
15.05
ADMA Biologics Inc. a biopharmaceutical company engages in developing manufacturing and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition it operates source plasma collection facilities. The company sells its products through independent distributors drug wholesalers specialty pharmacies and other alternate site providers. ADMA Biologics Inc. was incorporated in 2004 and is headquartered in Ramsey New Jersey.
View LessADMA | US
Risk
45.8
Sharpe
-0.23
Luna's Score
51/100
Recommendation
Hold
Luna says (ADMA | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Strong Operating Margin (> 25%)
Strong Revenue Growth (> 10%)
What's not Working
Price Below SMA10D
High Short-term Volatility
Midcap (2B - 10B USD)
High Debt to Equity (> 0.75)
Rich in Valuation (Price to Book > 8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
55.7%1 month
45.8%3 months
40.4%6 months
45.0%Returns
Fundamental Ratios
PE
112.71
Fwd. PE
23.20
Price to book
19.54
Debt to equity
0.75
Debt to assets
0.38
Ent. to EBITDA
55.11
Ent. to rev.
11.30
PEG
-
Other Fundamentals
EBITDA
95.09M
MarketCap
3.69B
MarketCap(USD)
3.69B
Div. yield
-
Op. margin
36.57
Erngs. growth
-
Rev. growth
78.30
Ret. on equity
20.77
Short ratio
2.38
Short perc.
7.55
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
2.61
Range1M
2.61
Range3M
5.91
Volumes: Market Activity
Rel. volume
0.89
Price X volume
48.32M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 55.11 | - | Expensive |
| Ent. to Revenue | 11.30 | - | Cheaper |
| PE Ratio | 112.71 | 41.03 | Expensive |
| Price to Book | 19.54 | 15.55 | Expensive |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 40.42 | - | Lower Risk |
| Debt to Equity | 0.75 | -1.23 | Expensive |
| Debt to Assets | 0.38 | 0.25 | Expensive |
| Market Cap | 3.69B | - | Par |
